Large-cap Health Care company AstraZeneca PLC moved -2.5% Friday on a volume of 5,921,966, compared to its average of 4,191,637. In contrast, the S&P 500 index moved -1.0%.
AstraZeneca PLC trades -10.13% away from its average analyst target price of $80.25 per share. The 8 analysts following the stock have set target prices ranging from $65.0 to $88.0, and on average have given AstraZeneca PLC a rating of buy.
Anyone interested in buying AZN should be aware of the facts below:
-
AstraZeneca PLC's current price is 1112.5% above its Graham number of $5.95, which implies that at its current valuation it does not offer a margin of safety
-
AstraZeneca PLC has moved 8.4% over the last year, and the S&P 500 logged a change of 11.5%
-
Based on its trailing earnings per share of 1.49, AstraZeneca PLC has a trailing 12 month Price to Earnings (P/E) ratio of 48.4 while the S&P 500 average is 15.97
-
AZN has a forward P/E ratio of 16.9 based on its forward 12 month price to earnings (EPS) of $4.27 per share
-
The company has a price to earnings growth (PEG) ratio of 1.51 — a number near or below 1 signifying that AstraZeneca PLC is fairly valued compared to its estimated growth potential
-
Its Price to Book (P/B) ratio is 37.61 compared to its sector average of 4.16
-
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.
-
Based in Cambridge, the company has 83,500 full time employees and a market cap of $229.54 Billion. AstraZeneca PLC currently returns an annual dividend yield of 3.9%.